Oncology Drugs
Elvina Almuradova
Elvina Almuradova and Komal Jhaveri

Elvina Almuradova: Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

Elvina Almuradova, Ambassador at European School of Oncology, shared an article Komal Jhaveri and her colleagues authored on X:

“New in NEJM!!!

Imlunestrant shows promise in ER+/HER2- advanced breast cancer with ESR1 mutations – PFS 5.5 vs 3.8 months vs standard therapy. Adding Abemaciclib boosts PFS to 9.4 months.”

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

Authors: Komal L. Jhaveri et al.

Elvina Almuradova

Imlunestrant and Abemaciclib: A Study in Advanced Breast Cancer
André Mattar Antonio Llombart-Cussac Breast Cancer cancer Chih-Chiang Hung Chiun-Sheng Huang Christoph Cramer von Laue Cristina Saura Elgene Lim Emily Barrett Eriko Tokunaga François-Clément Bidard Giuseppe Curigliano Joohyuk Sohn Jorge Luis Martinez Rodriguez Joyce O'Shaughnessy Kamnesh R. Pradhan Komal L. Jhaveri Lillian M. Smyth Lisa A. Carey Manuel Ruiz Borrego María de la Luz García Tinoco Monica Lis Casalnuovo Nadia Harbeck OncoDaily Oncology Patrick Neven Philippe Aftimos Qingyuan Zhang Rikiya Nakamura Shanshan Cao Sung-Bae Kim Xuejing Aimee Wang